Study: NCT04524871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1120
Description: TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 2100 mg
Description: Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg
Description: Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 600 mg
Description: Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 1200 mg
Description: Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG126
Description: ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO-108 1800 mg
Description: IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.